AQSZF - Aequus Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1178
-0.0096 (-7.54%)
At close: 2:40PM EST
Stock chart is not supported by your current browser
Previous Close0.1274
Open0.1200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1178 - 0.1297
52 Week Range0.1112 - 0.3560
Volume4,500
Avg. Volume24,493
Market Cap10.255M
Beta (3Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-0.0280
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire15 days ago

    Aequus Reports Largest Quarterly Revenue in Company History and Provides Management Update

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three and nine months ended September 30, 2018 and associated Company developments. Year to date revenue for the nine months ended September 30, 2018 of $1,173,013, a 52% increase over the same period in 2017. Decrease in net losses of 31% over the same quarter last year, and an overall 34% decrease in losses for nine months ended September 30 when compared to the same time period in 2017.

  • GlobeNewswirelast month

    Aequus Strengthens Clinical Experience on Strategic Advisory Board in Ophthalmology, and Adds Commercial and Regulatory Expertise

    VANCOUVER, British Columbia, Nov. 15, 2018 -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a.

  • GlobeNewswirelast month

    Aequus Hosts Live Webinar Demonstrating the Zepto® Capsulotomy System, Led by Dr. Ike Ahmed

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, is pleased to announce the successful presentation of a live webinar demonstrating the Zepto®  Precision Pulse Capsulotomy (“Zepto”) device’s ability to address challenging capsulotomy cases during cataract surgery. The webinar, hosted by Dr. Ike Ahmed, took place on Monday, November 12 and was attended by ophthalmologists across Canada interested in learning more about the product’s features and use within the clinic.

  • GlobeNewswirelast month

    Aequus forms Strategic Advisory Board in Ophthalmology, Chaired by Dr. Ike Ahmed

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the formation of a strategic advisory board in ophthalmology with the appointment of its first two members, Dr. Ike Ahmed of the Prism Eye Institute joining as Chairman, and Dr. Rosa Braga-Mele of the University of Toronto. Aequus has formed the Advisory Board to assist in assessing and rationalizing the many ophthalmology pipeline opportunities, both in therapeutics and medical devices, available to the Company.

  • CNW Group9 months ago

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

    Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis